AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9357360 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures with social messages
Number of subjects: 0
Study 9357360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8448072 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 12
Study 8448072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 12
Study 8448072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3606915 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. lignocaine 1.5 mg kg‐1 plus 2 mg kg‐1 h‐1
Number of subjects: 18
Study 3606915 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study 29581536 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 61
Study 29581536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28069870 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels
Number of subjects: 642
Study 26081662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion plus hemodialysis (HP+HD)
Number of subjects: 66
Study 26081662 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 66
Study 26081662 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 66
Study 23115322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-blockers
Number of subjects: 957
Study 23115322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beta-blockers
Number of subjects: 957
Study 23115322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker dose
Number of subjects: 957
Study 23115322 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 957
Study 22010234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis KD1 at 10^9, 5 × 10^9, and 10^10 bacilli/kg of feed
Number of subjects: 0
Study 22010234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18598160 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 29
Study 18598160 — intervention group
Group type: COMPARATOR
Intervention: Aerolizer
Number of subjects: 29
Study 19657788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated reactive hyperemia by digital tonometry (RHI)
Number of subjects: 102
Study 19657788 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 102
Study 19657788 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol
Number of subjects: 102
Study 19657788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT)
Number of subjects: 102
Study 19657788 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary arterial calcium (CAC)
Number of subjects: 102
Study 15573391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic fibrinolysis with urokinase after chest tube drainage
Number of subjects: 100
Study 15573391 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 100
Study 15573391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest drain insertion
Number of subjects: 100
Study 15573391 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 12011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 12.5 mg
Number of subjects: 100
Study 12011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 5.0 mg
Number of subjects: 100
Study 12011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 2.5 mg
Number of subjects: 100
Study 12011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (all dosages)
Number of subjects: 100
Study 12011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (per mg increase)
Number of subjects: 100
Study 9972338 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 30
Study 7914122 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol (Pd) single dose of 0.04-0.08 g
Number of subjects: 12
Study 7914122 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (Pr) single dose of 0.04-0.08 g
Number of subjects: 12
Study 7914122 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol (Pd) course treatment mean daily dose of 186 +/- 24 mg
Number of subjects: 12
Study 7914122 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (Pr) course treatment mean daily dose of 182 +/- 25 mg
Number of subjects: 12
Study 7914122 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol (Pd) single dose of 0.04 g
Number of subjects: 12
Study 7914122 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (Pr) single dose of 0.04 g
Number of subjects: 12
Study 7914122 — intervention group
Group type: COMPARATOR
Intervention: Proxodolol (Pd) and Propranolol (Pr) during course therapy
Number of subjects: 12
Study 3378465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (preoperative and four postoperative doses)
Number of subjects: 70
Study 3378465 — intervention group
Group type: COMPARATOR
Intervention: Control (no parenteral antibiotics)
Number of subjects: 70
Study 31112380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 4000
Study 31112380 — intervention group
Group type: COMPARATOR
Intervention: Usual care (propofol, midazolam, or other sedatives)
Number of subjects: 4000
Study 31112380 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4000
Study 29212515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 26773539 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stretching exercises
Number of subjects: 80
Study 26773539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching exercises)
Number of subjects: 80
Study 24589330 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-4 skeletal metastases
Number of subjects: 561
Study 24589330 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-20 skeletal metastases
Number of subjects: 561
Study 24589330 — intervention group
Group type: EXPERIMENTAL
Intervention: >20 skeletal metastases
Number of subjects: 561
Study 24589330 — intervention group
Group type: COMPARATOR
Intervention: ≥5 skeletal metastases
Number of subjects: 561
Study 21842333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence prevention program (Building a Lasting Love, 4 sessions)
Number of subjects: 72
Study 21842333 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 72
Study 19200607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling Symptom Assessment Scale (G‐SAS)
Number of subjects: 207
Study 17551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol and betamethasone dipropionate (Dovobet/Daivobet/Taclonex)
Number of subjects: 0
Study 17551662 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15287544 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with distilled water
Number of subjects: 180
Study 15287544 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with anesthetic solution
Number of subjects: 180
Study 15287544 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with camphorated p‐monochlorophenol
Number of subjects: 180
Study 15287544 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with camphorated p‐monochlorophenol‐propylene glycol
Number of subjects: 180
Study 15287544 — intervention group
Group type: EXPERIMENTAL
Intervention: All calcium hydroxide pastes
Number of subjects: 180
Study 11204805 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-1 (acidified milk)
Number of subjects: 53
Study 11204805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9596107 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled beta2-agonist (fenoterol) treatment
Number of subjects: 64
Study 7786691 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium 15 mmol/day
Number of subjects: 39
Study 7786691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3149455 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (200 micrograms subcutaneously daily or 400 micrograms intranasally three times daily)
Number of subjects: 160
Study 3149455 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 160
Study 3149455 — intervention group
Group type: COMPARATOR
Intervention: DES/orchiectomy
Number of subjects: 160
Study 3149455 — intervention group
Group type: COMPARATOR
Intervention: Buserelin and DES/orchiectomy
Number of subjects: 160
Study 29338146 — intervention group
Group type: EXPERIMENTAL
Intervention: High liberal group (15 mL/kg/hr intraoperatively and 10 mL/kg/hr six hours postoperatively)
Number of subjects: 90
Study 29338146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low liberal group (5 mL/kg/hr intraoperatively and six hours postoperatively)
Number of subjects: 90
Study 29338146 — intervention group
Group type: COMPARATOR
Intervention: Restrictive group (1 mL/kg/hr intraoperatively and six hours postoperatively)
Number of subjects: 90
Study 25780260 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth's 3D exercises in the clinic
Number of subjects: 51
Study 25780260 — intervention group
Group type: COMPARATOR
Intervention: Schroth's 3D exercises at home
Number of subjects: 51
Study 25780260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 24201760 — intervention group
Group type: EXPERIMENTAL
Intervention: Real peripheral prism glasses (57-prism diopter oblique)
Number of subjects: 73
Study 24201760 — intervention group
Group type: COMPARATOR
Intervention: Sham peripheral prism glasses (<5-prism diopter horizontal)
Number of subjects: 73
Study 24201760 — intervention group
Group type: EXPERIMENTAL
Intervention: Real peripheral prism glasses
Number of subjects: 73
Study 24201760 — intervention group
Group type: COMPARATOR
Intervention: Sham peripheral prism glasses
Number of subjects: 73
Study 23422913 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-3781 100 mg
Number of subjects: 210
Study 23422913 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-3781 150 mg
Number of subjects: 210
Study 23422913 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g every 12 h
Number of subjects: 210
Study 23422913 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 210
Study 20825674 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 473
Study 17579613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation (CRYO)
Number of subjects: 64
Study 17579613 — intervention group
Group type: COMPARATOR
Intervention: External beam radiation (EBRT)
Number of subjects: 64
Study 16970093 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuquan Pill (YP) 6 g four times a day for 3 months
Number of subjects: 90
Study 16970093 — intervention group
Group type: COMPARATOR
Intervention: Glucobay with dietary and exercise therapy for 3 months (Control)
Number of subjects: 90
Study 12113275 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis
Number of subjects: 80
Study 12113275 — intervention group
Group type: COMPARATOR
Intervention: Contrast radiography
Number of subjects: 80
Study 9987507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg/day
Number of subjects: 17
Study 9987507 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 40 mg/day
Number of subjects: 17
Study 9987507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg/day
Number of subjects: 17
Study 8846678 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glibenclamide
Number of subjects: 10
Study 8846678 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 10
Study 8846678 — intervention group
Group type: COMPARATOR
Intervention: Insulin and placebo
Number of subjects: 10
Study 2227085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical tretinoin
Number of subjects: 0
Study 681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy set condition with belief of consuming alcohol
Number of subjects: 48
Study 681614 — intervention group
Group type: COMPARATOR
Intervention: Expectancy set condition with belief of consuming nonalcoholic beverage
Number of subjects: 48
Study 681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic malt liquor
Number of subjects: 48
Study 681614 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic malt beverage
Number of subjects: 48
Study 681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive set (expectancy)
Number of subjects: 48
Study 681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 48
Study 28737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted and stained teeth
Number of subjects: 433
Study 28737282 — intervention group
Group type: COMPARATOR
Intervention: White and aligned teeth
Number of subjects: 433
Study 28737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with ≥20 teeth
Number of subjects: 433
Study 28737282 — intervention group
Group type: COMPARATOR
Intervention: Participants with <20 teeth
Number of subjects: 433
Study 28737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with twisted and stained teeth
Number of subjects: 433
Study 28737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with twisted and stained teeth
Number of subjects: 433
Study 27364603 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) administered at baseline, 1.5 years, and 3 years.
Number of subjects: 716
Study 27364603 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) administered to distinguish between exacerbation status.
Number of subjects: 716
Study 27364603 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) administered to different demographic groups.
Number of subjects: 716
Study 24731917 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise and hypocaloric healthy eating program plus usual care
Number of subjects: 85
Study 24731917 — intervention group
Group type: COMPARATOR
Intervention: usual care alone
Number of subjects: 85
Study 22420843 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 86
Study 22420843 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 86
Study 20679551 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic cooling with rapid infusion of 2 L of ice-cold lactated Ringer's solution
Number of subjects: 234
Study 20679551 — intervention group
Group type: COMPARATOR
Intervention: Hospital cooling (cooling after hospital admission)
Number of subjects: 234
Study 20679551 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic cooling
Number of subjects: 234
Study 20679551 — intervention group
Group type: COMPARATOR
Intervention: Hospital cooling
Number of subjects: 234
Study 18602242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs (image matrices)
Number of subjects: 631
Study 18602242 — intervention group
Group type: COMPARATOR
Intervention: Numeric text only
Number of subjects: 631
Study 18602242 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental risk formats
Number of subjects: 631
Study 16330196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast for 4 weeks
Number of subjects: 23
Study 16330196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive treatment)
Number of subjects: 23
Study 12817518 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 and MDR1 polymorphic expression
Number of subjects: 19
Study 12817518 — intervention group
Group type: COMPARATOR
Intervention: MDR1 C3435T genotype
Number of subjects: 19
Study 10937516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day)
Number of subjects: 50
Study 10937516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9132333 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary fibromyalgia patients
Number of subjects: 32
Study 9132333 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 32
Study 7522529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive immunoradiometric assays (IRMA)
Number of subjects: 127
Study 7522529 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) followed by successful renal transplantation
Number of subjects: 127
Study 7522529 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 127
Study 3789755 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and/or combination chemotherapies (ACOP, ACOP‐E and AclBEP regimens)
Number of subjects: 92
Study 29304735 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine 0.5 μg.kg‐1 (Group DEX, n=30)
Number of subjects: 60
Study 29304735 — intervention group
Group type: COMPARATOR
Intervention: IV saline (Group P, n=30)
Number of subjects: 60
Study 28031021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptability treadmill training
Number of subjects: 70
Study 28031021 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treadmill training
Number of subjects: 70
Study 28031021 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy
Number of subjects: 70
Study 23736797 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 45
Study 22429373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin‐added haemostatic matrix (THM)
Number of subjects: 50
Study 22429373 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery plus hot compressor application
Number of subjects: 50
Study 20384528 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 19
Study 20384528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18343242 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (30 mg nifedipine)
Number of subjects: 12
Study 18343242 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (30 mg nifedipine)
Number of subjects: 12
Study 15928362 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 257
Study 11673340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression (n=380)
Number of subjects: 804
Study 11673340 — intervention group
Group type: COMPARATOR
Intervention: Patients without depression (n=424)
Number of subjects: 804
Study 11673340 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model analysis (including age, sex, diabetes, present cigarette smoking)
Number of subjects: 804
Study 9493517 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months)
Number of subjects: 291
Study 9493517 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalating regimen of interferon-alpha2a (6 MIU three times a week for 3 months followed by 3 MIU three times a week for 3 months)
Number of subjects: 291
Study 9493517 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months) in non-cirrhotic patients
Number of subjects: 291
Study 9493517 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalating regimen of interferon-alpha2a (6 MIU three times a week for 3 months followed by 3 MIU three times a week for 3 months) in non-cirrhotic patients
Number of subjects: 291
Study 9493517 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients with sustained response
Number of subjects: 291
Study 9493517 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT activity assessed at month 1
Number of subjects: 291
Study 8299884 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (46%)
Number of subjects: 105
Study 8299884 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (24%)
Number of subjects: 105
Study 3191075 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 26
Study 3191075 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine
Number of subjects: 26
Study 3191075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% adrenaline
Number of subjects: 26
Study 3191075 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 26
Study 7982429 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1.5 g orally for 6 months)
Number of subjects: 50
Study 7982429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 419810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclane 100 mg
Number of subjects: 17
Study 419810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclane 200 mg
Number of subjects: 17
Study 31461548 — intervention group
Group type: EXPERIMENTAL
Intervention: Test regimen (4% niacinamide + Simple® Kind to Skin Moisturizing Facial Wash)
Number of subjects: 132
Study 31461548 — intervention group
Group type: COMPARATOR
Intervention: Positive control (4% niacinamide + Neutrogena Visibly Clear® Spot Clearing Facial Wash)
Number of subjects: 132
Study 31461548 — intervention group
Group type: COMPARATOR
Intervention: Control (no moisturizer + Simple® Kind to Skin Moisturizing Facial Wash)
Number of subjects: 132
Study 31669451 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE) combined with 50 mg D-Cycloserine (DCS)
Number of subjects: 0
Study 31669451 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE) combined with 50 mg D-Cycloserine (DCS)
Number of subjects: 0
Study 31669451 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study 31669451 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 0
Study 31669451 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Prolonged Exposure Therapy (PE)
Number of subjects: 0
Study 31669451 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study 28357969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209